Notably, lorlatinib, the latest FDA-approved ALK inhibitor for NSCLC (The Asco Post, 2018), has demonstrated favorable pharmacokinetics properties, including ADME (absorption, distribution, metabolism, and excretion) parameters. The gene discussed is ALK; the disease is non-small cell lung carcinoma.